400 Farmington Avenue
6 articles with Imstem Biotechnology
ImStem Biotechnology, Inc., a biopharmaceutical company pioneering the development of human embryonic stem cell derived mesenchymal stem cells through a proprietary method using a trophoblast intermediate stage, announced the dosing of the first US multiple sclerosis patient with its lead investigational drug candidate IMS001 at the Shepherd Center in Atlanta, GA.
AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute Respiratory Distress Syndrome
Emerging Preclinical and Clinical Data Support Potential of Mesenchymal Stem Cells (MSCs) to be Useful in COVID-19 and Acute Respiratory Distress Syndrome (ARDS) from Other Causes ImStem’s MSC Product Candidate IMS001 is Derived from AgeX’s Stem Cell Line ESI-053 IMS001, which Recently Gained FDA IND Clearance to Begin Human Study in Multiple Sclerosis, to be Considered for Development in COVID-19 and ARDS More Generally
AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other Causes of ARDS
Emerging preclinical and clinical literature support MSCs may be appropriate to develop for COVID-19 as well as non-COVID-19 ARDS ImStem’s investigational MSC candidate IMS001, for which FDA recently removed a clinical hold on an IND to begin a human study in multiple sclerosis, to be considered for further development in COVID19 and ARDS from other causes IMS001 is derived from AgeX human embryonic stem cell line ESI 053
3/30/2020Although some clinical trials are being slowed or halted, others are reporting out data. Here’s a look.
ImStem Biotechnology Announces FDA has Lifted the Clinical Hold on the Investigational New Drug Application for IMS001 for the Treatment of Multiple Sclerosis
ImStem Biotechnology, Inc. announced that the U.S. Food and Drug Administration has lifted the clinical hold and cleared the Investigational New Drug application to evaluate IMS001 for the treatment of multiple sclerosis.